Amgen Inc. (AMGN)
Nasdaq: AMGN · Biological Products, (No Diagnostic Substances) · Thousand Oaks, CA · filing with the SEC since 1994
Grade6.8
◀ Past 7.1● Present 7.7▶ Future 5.2
Who owns Amgen Inc.
As filed with the SECHolders of 5% or more
3
Blackrock, Inc. holds 7.6% of Common Stock, as its SCHEDULE 13G/A filed Apr 17, 2025 says.
Directors and officers
24
report now, of 45 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 17, 2025 · Common Stock
Vanguard Capital Management
SCHEDULE 13G · filed Apr 29, 2026 · Common Stock
Capital World Investors
SCHEDULE 13G · filed May 14, 2026 · Common Stock
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%, from 10% in Sep 8, 2025
What AMGN reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Horizon Therapeutics
A company bought · acquisition · Sep 2023 · owns, named in the 10-K filed Feb 13, 2026
42 subsidiaries in 14 countries, from the list filed with the 10-K filed Feb 13, 2026.
Insider tradesForm 4
14sales
0purchases
0sales on a scheduled plan
6people selling
$29.3Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 9, 2025 to Nov 9, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 9, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window6 of 45 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Santos Esteban | EVP, Operations | 2 | $20.8M | 0 | 0 | $0 |
| Grygiel Nancy A. | SVP & CCO | 5 | $2.7M | 0 | 0 | $0 |
| Gordon Murdo | EVP, Global Commercial Ops | 1 | $2.3M | 0 | 0 | $0 |
| Khosla Rachna | SVP, Business Development | 3 | $1.6M | 0 | 0 | $0 |
| Miller Derek | SVP, Human Resources | 2 | $1.6M | 0 | 0 | $0 |
| Busch Matthew C. | VP, Finance & CAO | 1 | $400,000 | 0 | 0 | $0 |